As Colorado’s Prescription Drug Affordability Board (PDAB) moves to control the price of drugs, patients’ costs are not reduced, but their access to medicines is at risk, Bio.News reports.
What’s happening: Colorado’s PDAB is reviewing certain drugs to decide whether the state will impose an upper payment limit (UPL)— (a.k.a. price cap) for drugs provided in markets regulated by the state.
PDABs, in a nutshell: State boards that aim to cap, control, and dictate the price of drugs that manufacturers can charge.
Everyone’s watching: “Colorado’s PDAB model is one that a lot of states are looking at,” says Patrick Plues, BIO’s VP of State Government Affairs. While Maryland was the first state to pass a PDAB, the “Maryland PDAB’s oversight applied only to state and local purchasers. But comparatively, Colorado was the first state to pass a PDAB that applied to the commercial market as well.”
The bottom line: Colorado’s PDAB “must tread carefully to ensure Colorado does not harm patients in its quest to be the first in the nation to implement this experimental program,” says a letter from the Colorado Bioscience Association.
Read more on Bio.News.